243 related articles for article (PubMed ID: 19852718)
1. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
Washburn WN
Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
[TBL] [Abstract][Full Text] [Related]
2. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
3. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Washburn WN
J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
[No Abstract] [Full Text] [Related]
4. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
[TBL] [Abstract][Full Text] [Related]
5. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
[No Abstract] [Full Text] [Related]
6. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
[TBL] [Abstract][Full Text] [Related]
7. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
[TBL] [Abstract][Full Text] [Related]
8. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
[TBL] [Abstract][Full Text] [Related]
9. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
12. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.
Pfister M; Whaley JM; Zhang L; List JF
Clin Pharmacol Ther; 2011 Apr; 89(4):621-5. PubMed ID: 21346749
[No Abstract] [Full Text] [Related]
14. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
[TBL] [Abstract][Full Text] [Related]
15. Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
Nat Rev Drug Discov; 2010 Mar; 9(3):182. PubMed ID: 20190779
[No Abstract] [Full Text] [Related]
16. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.
Machado UF; Corrêa-Giannella ML
Expert Opin Emerg Drugs; 2014 Mar; 19(1):5-9. PubMed ID: 24397354
[TBL] [Abstract][Full Text] [Related]
20. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
